Effects of eicosapentaenoic acid on peri-procedural (type IVa) myocardial infarction following elective coronary stenting  by Kurita, Akiyoshi et al.
Journal of Cardiology 66 (2015) 114–119Original article
Effects of eicosapentaenoic acid on peri-procedural (type IVa)
myocardial infarction following elective coronary stenting
Akiyoshi Kurita (MD)a, Hiroaki Takashima (MD)a, Hirohiko Ando (MD)a,
Soichiro Kumagai (MD)a, Katsuhisa Waseda (MD)a, Masahiko Gosho (PhD)b,
Tetsuya Amano (MD, PhD)a,*
aDepartment of Cardiology, Aichi Medical University, Nagakute, Japan
bAdvanced Medical Research Center, Aichi Medical University, Nagakute, Japan
A R T I C L E I N F O
Article history:
Received 26 May 2014
Received in revised form 1 September 2014
Accepted 5 September 2014
Available online 23 October 2014
Keywords:
n-3 PUFAs
Peri-procedural myocardial infarction
Lipid proﬁles
A B S T R A C T
Objectives: The aim of this study was to assess the effect of eicosapentaenoic acid (EPA) on peri-
procedural (type IVa) myocardial infarction (MI) following elective percutaneous coronary intervention
(PCI).
Methods and results: We analyzed data from 165 of 178 consecutive patients with stable angina pectoris
who underwent de novo successful stent implantation in the native coronary artery. Patients were
assigned to receive statin therapy in combination with 1800 mg/day of EPA or statin alone. Post-
procedural index of microcirculatory resistance (IMR) values were calculated for 30 patients in the EPA
group and 32 controls. In the multivariate logistic model, EPA administration, low kidney function, and
the presence of slow ﬂow/no reﬂow were signiﬁcantly and independently associated with type IVa MI.
Post-procedural IMR values were signiﬁcantly lower in the EPA group [19.8 (6.4, 51.1) vs. 27.8 (8.2, 89.3),
p = 0.003] compared to the control group.
Conclusions: Pre-treatment with EPA in addition to statins signiﬁcantly reduced the incidence of type IVa
MI compared to statin therapy only, which may be attributed to the ability of EPA to reduce
microvascular dysfunction induced by PCI.
 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Peri-procedural (type IVa) myocardial infarction (MI) after
successful percutaneous coronary intervention (PCI) is common
[1,2]. A number of studies have shown a correlation between type
IVa MI and adverse clinical outcomes [3,4]. Statins, which are
widely used to decrease low-density lipoprotein (LDL) cholesterol
levels, have been shown to reduce the occurrence of type IVa MI
[5–7]. Although the underlying mechanism by which statins exert
their beneﬁcial preventive effects on type IVa MI remains elusive,
pleiotropic effects beyond LDL cholesterol level reduction have
been advocated [8]. In a similar vein, n-3 polyunsaturated fatty
acids (PUFAs) also have several anti-arteriosclerotic effects,
including reduced platelet aggregation [9,10], vasodilation
[11,12], and inhibition of atherosclerosis [13], which play a critical
role in the prevention of type IVa MI [14].* Corresponding author at: Department of Cardiology, Aichi Medical University
Yazako-Karimata, Nagakute city 480-1195, Japan. Tel.: +81 561 62 3311;
fax: +81 561 61 1958.
E-mail address: amanot@aichi-med-u.ac.jp (T. Amano).
http://dx.doi.org/10.1016/j.jjcc.2014.09.004
0914-5087/ 2014 Published by Elsevier Ltd on behalf of Japanese College of CardioloWe therefore conducted the present study to examine the
effects of eicosapentaenoic acid (EPA), a pure n-3 PUFA, in addition
to chronic statin treatment on reducing type IVa MI following an
elective PCI in patients with stable angina pectoris (SAP), taking
into account possible related clinical and procedural factors.
Methods
Patients and study design
This study was a prospectively planned non-randomized
clinical trial conducted at Aichi Medical University. A total of
178 consecutive patients who underwent an elective and de novo
stent implantation in the native coronary artery for SAP between
March 2011 and May 2013 were prospectively assigned to receive
statin or statin together with EPA treatment. It is considered
continuous daily treatment for at least 1 month before PCI, when
all patients received any statin as ﬁrst-line treatment for more than
1 month. Eligible patients were stratiﬁed based on treatment
status as follows: patients who received oral EPA 900 mg BID (the
recommended dosage in Japan) in addition to statin therapy (EPAgy.
Table 1
Baseline characteristics.
Variable EPA use p value
Yes No
n = 82 n = 83
Male 62 (76) 58 (70) 0.49
Age (years) 68  9 69  9 0.49
Body mass index
(kg/m2)
24  4 24  3 0.33
Diabetes mellitus 48 (59) 39 (47) 0.16
Hypertension 59 (72) 71 (86) 0.04
Current smoker 17 (21) 15 (18) 0.70
ACEI or ARB 48 (59) 59 (71) 0.10
Beta blocker 31 (38) 34 (41) 0.75
Statins 82 (100) 83 (100) 1.00
Atorvastatin 11 (13) 9 (11)
Fluvastatin 3 (4) 2 (2)
Pitavastatin 48 (59) 49 (59)
Pravastatin 1 (1) 2 (2)
Rosuvastatin 11 (13) 7 (8)
Simvastatin 2 (2) 1 (1)
Others 6 (7) 13 (16)
P2Y12 inhibitors 81 (99) 79 (95) 0.37
Aspirin 82 (100) 83 (100) 1.00
eGFR
(ml/min/1.73 m2)
63  25 60  22 0.51
Hs-CRP (ng/mL) 685 [0, 14200] 722 [0, 14300] 0.93
LDL cholesterol
(mg/dL)
87  28 95  28 0.07
HDL cholesterol
(mg/dL)
46  11 46  13 0.75
Triglycerides
(mg/dL)
114 [40, 373] 131 [52, 793] 0.12
EPA (mg/mL) 158.3 [29.9, 419.6] 49.1 [17.9, 270.8] <0.001
DHA (mg/mL) 123.2 [2.5, 313.6] 121.4 [6.7, 563.7] 0.63
AA (mg/mL) 162.5 [65.5, 364.6] 165.3 [97.8, 299.8] 0.46
EPA/AA 0.88 [0.16, 2.88] 0.30 [0.09, 1.02] <0.001
Values are the mean  SD or number of patients or median [range]. ACEI,
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker;
eGFR, estimated glomerular ﬁltration rate; Hs-CRP, high sensitivity C reactive
protein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid; AA, arachidonic acid.
The ﬁgures in brackets are minimum and maximum values.
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group). EPA was administered in 89 consecutive patients who
underwent PCI between May 2012 and May 2013; the median
length of EPA treatment before PCI was 27 days. A total of
89 consecutive patients treated with statin therapy only (control
group) underwent PCI between March 2011 and May 2012. Exclu-
sion criteria were as follows: use of distal protection device
(4 patients), angioplasty with atherectomy (5 patients), and
occlusion of a side branch originating from a stented segment
(4 patients). Ultimately, 165 patients with 165 de novo stent
implantations (82 patients in EPA group and 83 in control group)
who fulﬁlled the inclusion criteria were included in the data
analysis. All patients had angina, documented myocardial ische-
mia, or both. This study was approved by the ethics committee of
Aichi Medical University and all patients provided informed
consent.
Data collection and laboratory examinations
Blood was sampled prior to and 16–20 h after the procedure.
Various biomarkers were measured by using commercial radio-
immunoassay kits and speciﬁc immunoradiometric assays. The
detection limit of this system is 0.03 ng/mL and linearity is
achieved from 0.1 to 2 ng/mL. A level of troponin-T
(TnT) < 0.03 ng/mL was considered a negative result and any
reading from 0.03 up to 0.1 ng/mL was considered 0.1 ng/mL. We
deﬁned type IVa MI as three categories of post-procedural TnT
level of >0.1, >0.3, and >0.5 ng/mL, which was 1, 3, and 5 times the
normal limit (manufacturer’s clinical cut-off value: 0.1 ng/mL).
Deﬁnition of risk factors
Hypertension was deﬁned as a history or presence of hyperten-
sion with a systolic blood pressure >140 mmHg and/or diastolic
blood pressure >90 mmHg, or the presence of anti-hypertensive
treatment. Diabetes mellitus was deﬁned as a history of diabetes
mellitus, a fasting plasma glucose concentration >126 mg/dL, a
randomized plasma glucose concentration >200 mg/dL and/or the
presence of anti-hyperglycemic treatment. Smoking status was
deﬁned as current or cessation within 6 months before PCI.
PCI procedure and measurement of IMR
All patients were treated with aspirin 24 h prior to the
procedure. Before undergoing coronary angiography and PCI,
patients were given a 0.5 mg intracoronary dose of isosorbide
dinitrate to prevent coronary spasm. In quantitative coronary
angiography, reference diameter and percent diameter stenosis
were measured by using a validated automated edge-detection
program (CMS-MEDIS Medical Imaging System, Leiden, The
Netherlands). Slow ﬂow or no reﬂow were deﬁned as a substantial
ﬂow reduction (less than thrombolysis in myocardial infarction
3 ﬂow) in the absence of apparent dissection, thrombosis, or distal
vessel cut-off suggestive of macroembolization during PCI
procedure. The protocol recommended the use of appropriate
drugs such as verapamil and nicorandil when delayed coronary
opaciﬁcations were noted. The index of microcirculatory resistance
(IMR) was measured after PCI by using previously described
methods [15–17]. An intracoronary pressure/temperature sensor-
tipped wire (Radi PressureWire Certus, St. Jude Medical, Minnea-
polis, MN, USA) was through a 6-F or 7-F guiding catheter to
position the pressure sensor at a point far distal from the distal
edge of the stent. Intravenous adenosine triphosphate (140 mg/kg/
min) was administered to induce steady-state maximal hyper-
emia. Then, 3 injections of saline (3 ml at room temperature) were
administered into the coronary artery through the guiding catheterat maximal hyperemia. The hyperemic transit time was measured
as the time that elapsed between when half of the saline had been
injected and when one-half of the saline had passed the sensor.
IMR was then calculated as the mean distal coronary pressure
multiplied by the hyperemic mean transit time.
Statistical analyses
Continuous variables were summarized as mean  SD or
median (Min, Max). Differences between the EPA group and control
groups were compared by using Student’s t-test or Wilcoxon rank
sum test. Categorical variables were summarized as n (%) and were
compared between the two groups by using Fisher’s exact test. The
effects of EPA on the incidence of type IVa MI were analyzed by using
a multivariate logistic regression model, with EPA use, low kidney
function, and slow ﬂow, which yielded p-values <0.05 in the
univariate model as the predictive factors. Regarding absolute
changes in TnT levels, 3 groupings of serum EPA tertiles were
evaluated using analysis of variance (ANOVA) with Kruskal–Wallis
test. A p-value of <0.05 was considered statistically signiﬁcant.
Results
Baseline characteristics
Baseline patient and procedural characteristics are presented in
Tables 1 and 2. With the exception of a lower prevalence of
Table 2
Lesion and procedural characteristics.
Variable EPA use p value
Yes No
n = 82 n = 83
LAD 53 (65) 48 (58) 0.43
RCA 16 (20) 22 (27) 0.36
LCX 9 (11) 10 (12) 1.00
LMT 4 (5) 3 (4) 0.72
ACC/AHA lesion type B2C 53 (65) 40 (48) 0.049
Reference diameter (mm) 2.5  0.6 2.5  0.5 0.39
Lesion length (mm) 17.4  12.5 13.9  8.1 0.04
% diameter stenosis (%) 61  14 64  13 0.09
Stent diameter (mm) 3.0  0.4 3.0  0.4 0.75
Stents length (mm) 21.4  7.7 19.3  6.5 0.06
Slow ﬂow/no reﬂow 6 (7) 5 (6) 0.77
Type IVa MI
TnT > 0.1 ng/mL 10 (12) 23 (28) 0.019
TnT > 0.3 ng/mL 2 (2) 9 (11) 0.057
TnT > 0.5 ng/mL 1 (1) 5 (6) 0.21
LAD, left anterior descending artery; RCA, right coronary artery; LCX, left
circumﬂex artery; LMT, left main trunk; ACC, American College of Cardiology;
AHA, American Heart Association. MI, myocardial infarction; TnT, troponin-T. Fig. 2. Post-procedural index of microcirculatory resistance values with or
without EPA treatment. Post-procedural IMR was signiﬁcantly decreased in the
EPA group compared to the control group [19.8 (6.4, 51.1) vs. 27.8 (8.2, 89.3),
p = 0.003].
IMR, index of microcirculatory resistance; EPA, eicosapentaenoic acid.
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were no signiﬁcant baseline differences between EPA-treated
patients and controls. Serum levels of EPA were signiﬁcantly
increased in the EPA group in accordance with EPA administration,
while serum docosahexaenoic acid levels were similar in both
groups. Compared with the control group, patients in the EPA
group had signiﬁcantly longer lesions and a signiﬁcantly greater
incidence of complex lesions. The occurrence of slow ﬂow/no
reﬂow was similar in both groups. The incidence of type IVa MI
deﬁned as TnT > 0.1, TnT > 0.3, and TnT > 0.5 were 12%, 2%, and 1%
in the EPA group, and 28%, 11%, and 6% in the control group,
respectively.
Peri-procedural cardiac biomarkers and IMR
The absolute change from baseline in TnT and creatine kinase-
MB (CK-MB) is shown in Fig. 1. The change from baseline in TnT
was signiﬁcantly lower in the EPA group compared to the controlFig. 1. The change from baseline in troponin-T and creatine kinase-MB isoform.
Treatment with EPA signiﬁcantly reduced the change from baseline in TnT [(0.0 (0.0,
0.5) vs. 0.0 (0.0, 1.4), p = 0.01] compared with controls, while there were no
signiﬁcant differences in CK-MB between both groups.
TnT, troponin-T; EPA, eicosapentaenoic acid; CK-MB, creatine kinase-MB isoform.group [0.0 (0.0, 0.5) vs. 0.0 (0.0, 1.4), p = 0.01), while change from
baseline in CK-MB was similar in both groups. Post-procedural IMR
was randomly measured just after PCI in 30 EPA-treated patients
and 32 controls, and was found to be signiﬁcantly lower in the EPA
group compared to the control group [19.8 (6.4, 51.1) vs. 27.8 (8.2,
89.3), p = 0.003] (Fig. 2). There were no signiﬁcant differences in
baseline characteristics between the two groups except for high
EPA and EPA/arachidonic acid values in the EPA group (data not
shown).
Association between serum EPA levels and absolute changes from
baseline in TnT
Fig. 3 shows the relationship of serum EPA levels with absolute
changes in TnT. The increasing levels of serum EPA wereFig. 3. Association between serum EPA levels and absolute changes from
baseline in TnT. The increasing levels of serum EPA were signiﬁcantly associated
with the decreasing level of absolute change in TnT (p = 0.021).
EPA, eicosapentaenoic acid; TnT, troponin-T.
Table 3
Simple regression analysis with delta Troponin-T level as the dependent variable.
Variable 95% CI
Coefﬁcient Lower Upper p value
EPA use 0.08 0.13 0.02 0.009
eGFR 30 (ml/min/1.73 m2) 0.14 0.04 0.24 0.007
Age 0.000 0.004 0.003 0.78
Sex, male 0.03 0.04 0.09 0.44
Body mass index (kg/m2) 0.003 0.01 0.01 0.46
Diabetes 0.04 0.10 0.02 0.19
Hypertension 0.01 0.08 0.06 0.77
Smoker 0.06 0.02 0.13 0.13
ACEI or ARB use 0.04 0.10 0.02 0.21
Beta blocker 0.05 0.11 0.01 0.09
Hs-CRP (log-transformed) 0.003 0.02 0.03 0.56
LDL cholesterol (mg/dL) 0.001 0.002 0.000 0.24
HDL cholesterol (mg/dL) 0.001 0.004 0.001 0.37
Triglycerides (log-transformed) 0.012 0.10 0.16 0.66
EPA (mg/mL) 0.000 0.000 0.000 0.047
DHA (mg/mL) 0.000 0.000 0.000 0.27
AA (mg/mL) 0.001 0.001 0.000 0.032
EPA/AA 0.04 0.09 0.01 0.14
LAD 0.037 0.02 0.10 0.23
RCA 0.04 0.11 0.03 0.24
LCX 0.03 0.12 0.06 0.56
LMT 0.04 0.11 0.18 0.63
ACC/AHA lesion type B2C 0.003 0.06 0.06 0.91
Reference diameter 0.02 0.08 0.03 0.43
Lesion length 0.001 0.003 0.002 0.69
% diameter stenosis 0.000 0.002 0.002 0.85
Stent diameter 0.02 0.09 0.05 0.62
Stent length 0.003 0.001 0.007 0.17
Slow ﬂow/no reﬂow 0.18 0.07 0.30 0.002
EPA, eicosapentaenoic acid; eGFR, estimated glomerular ﬁltration rate; ACEI,
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; DHA, docosahex-
aenoic acid; AA, arachidonic acid; LAD, left anterior descending artery; RCA,
right coronary artery; artery; LCX, left circumﬂex artery; LMT, left main trunk;
ACC, American College of Cardiology; AHA, American Heart Association.
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change in TnT (ANOVA, p = 0.021).
Relationship of various parameters to the incidence of type IVa MI
Table 3 shows the simple regression analysis with delta TnT
level as the dependent variable. EPA use (p = 0.009), low kidney
function (p = 0.007), and the presence of slow ﬂow/no reﬂow
(p = 0.002) were signiﬁcantly associated with the post-procedural
increase in TnT level. Table 4 shows the multivariate logistic
regression analysis for type IVa MI deﬁned at various TnT cut-off
levels. The model included EPA use, low kidney function
(eGFR < 30 ml/min/1.73 m2), and the presence of slow ﬂow/no
reﬂow. EPA use (p = 0.006 in Model 1, and p = 0.02 in Model 2), low
kidney function (p = 0.01 in Model 1, and p = 0.01 in Model 2), and
the presence of slow ﬂow/no reﬂow (p = 0.03 in Model 1,
p = 0.006 in Model 2, and p = 0.02 in Model 3) proved to be
independent predictors of type IVa MI. In a subgroup analysis of
the present study, beneﬁcial effects of EPA administration on
reducing type IVa MI were observed especially in males, those
receiving no angiotensin-converting enzyme inhibitor/angiotensinTable 4
Multivariate logistic regression analysis for type IVa MI.
Type IVa MI variable Model 1 TnT > 0.1 OR (95% CI) p-value Model
EPA use 0.3 (0.12–0.70) 0.006 0.12 
eGFR <30 (ml/min/1.73 m2) 4.77 (1.40–16.3) 0.01 9.14 
Slow ﬂow/no reﬂow 4.54 (1.20–17.2) 0.03 10.5 (2
MI, myocardial infarction; TnT, troponin-T; OR, odds ratio; CI, conﬁdence of intervalreceptor blocker treatment, those with left anterior descending
artery (LAD) lesions, and those with stenting longer than 18 mm
(Fig. 4).
Discussion
In the present study, we found that pre-treatment with pure
EPA added to chronic statin therapy signiﬁcantly reduced the
incidence of type IVa MI in SAP patients who underwent elective de
novo coronary stenting. Furthermore, post-procedural IMR, an
invasive wire-based quantitative measure of microvascular
function, was signiﬁcantly lower in the EPA group compared to
the control group.
The size of type IVa MI correlates directly with the extent to
which the plaque volume is reduced (embolized) by PCI, because
more debris is sent downstream. Moreover, plaque composition
inﬂuences the extent of type IVa MI. PCI for plaques with large lipid
cores leads to greater degrees of myonecrosis, whereas ﬁbrous
plaques are relatively inert in this regard [18]. Indeed, we have
previously reported the direct correlation of a large lipid core with
the extent of type IVa MI [19]. Recently, Cawood et al. examined
the incorporation of n-3 PUFAs into subclinical atherosclerotic
plaques and their association with plaque inﬂammation and
stability, and showed that EPA was mainly incorporated in
atherosclerotic plaques and could have beneﬁcial effects on plaque
stability [20]. In the present study, the incidence of slow ﬂow/no
reﬂow, which is related to a large lipid core and is a signiﬁcant
predictor of type IVa MI [18,19], was similar between both groups
(7% and 6% in EPA and control group, respectively p = 0.77).
Although we recently reported an association between decreased
n-3 PUFAs and lipid-rich plaques [21], it appears that the effect of
EPA on reducing type IVa MI is not necessarily due to plaque
stabilization in the target lesion.
Statins, which are widely used to decrease LDL cholesterol
levels, have been shown to reduce the occurrence of type IVa MI.
Although the underlying mechanism by which statins exert their
beneﬁcial preventive effects of on type IVa MI remains elusive,
pleiotropic effects beyond LDL cholesterol level reduction such as
anti-inﬂammatory properties, antioxidant effects, increased nitric
oxide bioavailability, and improvement of endothelial dysfunction
[1], have been advocated. In a similar way, n-3 PUFAs also have
several anti-arteriosclerotic effects including inhibiting platelet
aggregation, inﬂammatory cytokine production, and the expres-
sion of adhesion molecules, which play a critical role in the
prevention of type IVa MI [14]. In the present study, pre-treatment
with EPA in addition to chronic statin therapy further reduced
post-procedural IMR (which is a critical determinant of type IVa
MI) compared to treatment with statin therapy alone. Taken
together with other results, the beneﬁcial preventive effect of EPA
treatment on type IVa MI appears to occur through the
improvement of microvascular function rather than the stabiliza-
tion of coronary plaques.
The management of type IVa MI in the setting of elective PCI
remains a matter of considerable controversy and uncertainty,
especially with regard to therapeutic implications [22–24].
Previous studies have reported the association of type IVa MI
with adverse events. However, these studies, which evaluate the 2 TnT > 0.3 OR (95% CI) p-value Model 3 TnT > 0.5 OR 95% CI p value
(0.02–0.70) 0.02 0.14 (0.01–1.34) 0.09
(1.72–48.3) 0.01 3.76 (0.35–40.0) 0.27
.00–56.2) 0.006 11.0 (1.57–77.2) 0.02
; EPA, eicosapentaenoic acid; eGFR, estimated glomerular ﬁltration rate.
Fig. 4. Adjusted hazard ratio (95% CI) of EPA treatment for various subgroups. Associations were consistent across the subgroups, including male vs. female, with vs.
without ACEI or ARB, LAD lesion vs. non-LAD lesion, and lesion length of 18 mm or more vs. lesion length of less than 18 mm.
EPA, eicosapentaenoic acid; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; LAD, left anterior descending artery.
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and long term-prognosis, have, in general, not excluded patients
with acute coronary syndromes, many of whom would have had
abnormal cardiac-biomarker levels at baseline [25,26]. In addition,
most peri-procedural myocardial infarcts are small in relation to
the magnitude of myonecrosis, especially in patients with SAP.
Although troponin may be too sensitive for the detection of minor
myocardial necrosis, an increase in peri-procedural troponin
greater than 3 and 8 times the normal limit was found to be
associated with long-term adverse outcomes [19]. In this study, on
multivariate logistic models, the beneﬁcial effects of EPA pre-
treatment on type IVa MI were observed in models by using TnT
>0.1 and 0.3 ng/mL as cut-off values for a type IVa MI.
The predictors of type IVa MI can be broadly categorized as
procedure-, lesion-, and patient-related risk factors [27–29]. The
major risk factors, in terms of frequency and potency, are complex
lesions (e.g. type B2C lesion), complex procedures (e.g. use of
rotational atherectomy), and associated complications (e.g. side-
branch occlusion). Since these factors might obscure the interpre-
tation of the effects of EPA treatment on type IVa MI, we excluded
cases of use of rotational atherectomy, and side-branch occlusion
originating from stented segment. Regarding patient-related risk
factors, renal failure has been shown to be the important
determinant of type IVa MI. In the present study, impaired renal
function was independently associated with the occurrence of type
IVa MI, consistent with previous reports. In addition, pre-
treatment with EPA added to chronic statin therapy tended to
lower the risk of type IVa MI in these patients, and appears to be a
favorable option for high-risk patients in terms of reducing type
IVa MI.
This study had several limitations. First, the study population
was relatively small. Second, there were no data regarding dietary
characteristics or lifestyle factors that may have inﬂuenced PUFA
levels and the occurrence of type IVa MI [30]. In addition, the
values of various serum fatty acids such as EPA, docosahexaenoic
acid, and arachidonic acid were measured after EPA treatment.
Therefore, we cannot make any ﬁrm conclusion as to the
correlation between these biomarkers at baseline and the increasein TnT. Finally, IMR values were available in nearly 40% of total
patients. Therefore, the mechanisms of the putative beneﬁcial
effects of EPA treatment added to chronic statin therapy are
speculative. These data alone are not sufﬁcient to inﬂuence
therapeutic decisions. We await further study to conﬁrm these
initial observations.
In conclusion, pre-treatment with EPA in addition to chronic
statin therapy signiﬁcantly reduced peri-procedural TnT levels and
the incidence of type IVa MI compared to treatment with statin
therapy alone, which may be partly attributed to the ability of EPA
to reduce PCI-induced microvascular dysfunction.
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